2023 CiteScore: 0.7
pISSN: 0044-6025
eISSN: 1735-9694
Editor-in-Chief:
Ahmadreza Dehpour, PharmD, PhD
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE).
Vol 36, No 1 (1998)
The present work compared the clinical efficacy of ropically applied vitamin D3 (Cholecalciferol), I a, 25 dihydroxy vitamin D3 (cakitriol) with calcipotriol (Dovonex} in the treatment of plaque psoriasis. A randomized, double - blind, left - right, vehicle controlled study to assess the therapeutic
efficacy and safety of Mice daily application of 1 pg/g and 5 fJ.g1g chalecakiferol. 1 pglg calcitriol and 50 Ilglg calcipotriol in /00 patients suffering from bilateral, symmetrical, moderate co severe plaque psoriasis was carried au!. Twice daily catcitriol and calcipotriol significantly improved erythema. thickness, seating an d global severity ofpsoriatic plaques, and was much more effective than vehicle (10% hard paraffin in white soft paraffin), but the diffua,ce ill clinical efficacy between cholecalciferol and vehicle was n()( statistically significant. all completion of study, clearance and marked improvement ofpsoriatic lesions was found in 4% of vitamin D 3 (1 /.1.glg) - treated, in 12% of vitamin D3 (5 !tglg) - treated, ill 48% of calcitriol (1/.1.glg)treated, and in 64% of calcipotriot (50 pglg) - treated. Mean sman levels of total calcium, albumin - adjusted total calcium, phosphorus, creatinine, and also mean values of a 24 h urine calcium, phosphorus. creatinine, an d mean urine calcium I creatinine ratio did not show clinically relevant changes in the baseline I end - point analysis. We conclude that topical . catcimol and calcipotrio! are effective and safe for the treamlau of plaque psoriasis.
Experimental and clinical investigations indicate that antibody production and Tvliclper 2 (TN2) cvtokinc pattern, cg; Irucrtcukinc - -I, 10 (JL.J, ILID) arc domin ant during pregnancy_ COflSCqllCIlI~"" The T-/iclpa 1 (THI) celts activities decrease in pregnancy. Thus the cell- mediated immunity is paniattv depressed. All these events help fetus as an allograft survives ill the mother's wems. III this research we: measured Tli cvtokincs in the sera of hcalthv prcgncl!lf and llOfl-preglJ{mr women (IL]. IL-I. intcrfron-gannna; IFN-y). Pregnant women '""1101"'(~d s(l,'lliftcaw decrease ill mean semm level of IL2 and IFN - Y. this means depression of cell- mediated immunity. This /illdillt; explains increased incidence oj some of the intmccllutvr injections ami survival 0/ the [ctus during pregnancy.
This study compare:.' [he results 0;,.1 outcome of live-donor transplantation between single-artery "',"' mull/pic-ana)' transplant kidneys. Cadaver kidneys with multiple vessels arc retrieved with a patch of the donor artery. 111is is not possible ill the !iI'C donation seuing. Therefore !i1'C donation of rcnal
allografts with multiple arteries is lIot a straiglnjorward surgery. We studied 22 muttiplc-anery live donor renal allografts among 223 renal transplantations in a sequential. prospective mOllTlCr [or 3 ynJrs. One-year gra{! survival was l)(j.:V:(, ill single-anery group and 95.5":{, in tlns muliplc . arIer)' group. III the singleartery group the complications wae: dctavcd gm[l [unction ill 3.5'7;, rean astomosis o[ tlu: v-essels in 2,9':k, transient post-transplant dialysis in 1. 5 (X" graft nephrectomy ill 2,5';{, AT"' ill 1":'(" Urine leak in 2.5':{', renal anav stenosis in O.5S'(" and lvmpho cclc ill 1%. NOlie: o] thcsc occurred in the
multiptc-oncry group. This difference is statistically significant IX~ = 8.10). Cold ischemia time: l"'(lS significantly lunger in lilt' multiple . anery group (panastomosis was not siglliftcanl~"' dlffaelll among lht' 2,1,'Youps (I = 1.255). Ttu: totat tcngtli of tile operation IVas IOllga ill lhe mutsiptc-oncry group (p < O. 00(5). In conclusion it is appareIH snas t lu: intra-op crativc complications. posi-operati vc complications and one-year grafr survival are ccnnparabtc ill
single - ane'Y' "'."'. mutsiptc - arrcry renal transplantation. tn other words, !i1'C - donor transptannuion with muliip!c . arIa)' reno! units is safe and has a good OI/lCO!1le.
2023 CiteScore: 0.7
pISSN: 0044-6025
eISSN: 1735-9694
Editor-in-Chief:
Ahmadreza Dehpour, PharmD, PhD
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE).
All the work in this journal are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |